1 / 35

MONOTERAPIA CON DARUNAVIR/RITONAVIR

MONOTERAPIA CON DARUNAVIR/RITONAVIR. Dr. Jose R Arribas UNIDAD VIH. Conflicto de intereses. He recibido becas de investigación y pagos como conferenciante y asesor de: Janssen Cilag Tibotec Abbott Bristol-Myers

maximus
Download Presentation

MONOTERAPIA CON DARUNAVIR/RITONAVIR

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MONOTERAPIA CON DARUNAVIR/RITONAVIR Dr. Jose R Arribas UNIDAD VIH

  2. Conflicto de intereses • He recibido becas de investigación y pagos como conferenciante y asesor de: • Janssen Cilag • Tibotec • Abbott • Bristol-Myers • La presentación revisa la utilización de inhibidores de la proteasa potenciados con ritonavir (Lopinavir/r, Atazanavir/r, Darunavir/r) en pautas no recogidas en ficha técnica.

  3. Monoterapia con IPs

  4. 100% 100% 80% 80% 60% 60% 40% 40% 20% 20% 0% 0% 12 12 24 24 36 36 48 48 0 16 32 48 64 80 96 0 0 16 16 32 32 48 48 Week Week Week Discontinued On study, HIV RNA >400 c/mL On study, HIV RNA 50–400 c/mL On study, HIV RNA <50 c/mL Monotherapy with LPV/r Study 613 – LPV/r Induction/maintenance OK – LPV/r Simplification MONARK – LPV/r Initial therapy

  5. A randomized multicenter study to compare the efficacy of a monotherapy of darunavir to a triple therapy with 2 nucleosides analogues combined to darunavir/r in HIV infected patients with full viral suppression. MONOI ANRS 136 C Katlama, MA Valantin, M Algarte-Genin, C Duvivier, S Lambert-Niclot, PM Girard, JM Molina, B Hosten, S Pakianather, G Peytavin, AG Marcelin, P Flandre. Abstract WELBB102

  6. MONOI Study Design 1 • Multicenter open label randomized study Randomisation 1:1 DRV/r (600/100 mg bid) Introduction DRV/r DRV/r (600/100 mg bid)+ 2 NRTIs W96 W-8 W48 W-10 W-4 Phase I Long-term follow-up Phase II Primary Endpoint • Main inclusion criteria • cART ≥ 18 months • CD4 count ≥ 200 cells/mm3 • HIV RNA <400 copies/ml in the last 18 months and <50 copies/ml at entry • No history of PI failure and naïve to darunavir

  7. MONOI Study Design 2 • Primary objective To demonstrate non-inferiority of DRV/r monotheray versus 2 NRTIs + DRV/r in patients with viral suppression ( per protocol population ) • Primary endpoint : virological success until W48 Virological failure is defined as • 2 consecutive HIV-1 RNA > 400 copies/ml within 2 weeks • Any ART modification or study withdrawal • Study power Power = 80% Non-inferiority margin of 10% ( 90% CI ) assuming success rates in both arms at W48 of 90% • ITT population All patients receiving drug at D0 (ITT exposed) • Per protocol (PP) populationexcluded Patients who withdrew (n=6) or discontinued Rx without VF or SAE (n=10) Patients who did not fulfill the inclusion criteria (n=5)

  8. DRV/r DRV/r + NRTIs MONOI Primary Endpoint W48

  9. MONOI Reasons for failure

  10. Virological Failures in DRV/r arm • HIV RNA and DRV PK data at time of failure pt # 1 : W8 2722 cp/mlLow C24h 1120 ng/ml pt # 2 : W24 411cp/ml Adequate C24h 3480 ng/ml pt # 3 : W32 484.569 cp/mlTreatment discontinuation • No new DRV resistance mutations in the 3 patients • In all 3 patients, intensification with 2 NRTIs added to DRV/r, led to HIV RNA <50 copies/ml

  11. Proportion of patients with HIV RNA < 50 copies /ml : ITT population 92.0% 86.6% % Patients with HIV RNA < 50 cp/ml

  12. MONET - Trial Design Taking 2 NRTI + either NNRTI or boosted PI at screening (stratified) No prior use of darunavir (DRV) HIV RNA <50 copies/mL for at least 6 months, No history of virological failure DRV/r 800/100 mg OD + 2 NRTI (re-optimised at baseline) n = 129 Follow-up phase 96 weeks 256 subjects No run-in period DRV/r 800/100 mg OD n = 127 Follow-up phase 96 weeks 96 wks BL SC 30 days 4, 12, 24, 36, 48 weeks • Primary Endpoint:HIV RNA< 50 at week 48 (TLOVR). Per Protocol, Switch = Failure • 2 consecutive HIV RNA > 50 copies/mL (Roche Amplicor HIV-1 Monitor assay 1.5) • Stopping DRV/r • Starting NRTIs in the monotherapy arm • Stopping NRTIs in the triple therapy arm (switches in NRTIs were permitted at any time). J. Arribas et al, IAS Conference, Cape Town, SA, 21 July 2009, TUAB106-LB

  13. MONET: Baseline Characteristics (ITT) Age, years (median, range) Male (%) Caucasian (%) 43 (24-72) 83% 90% 43 (25-67) 78% 92% 579 12% 6.4 (4.0) 57% 43% 48% 28% 2 (1.6%) 14 (11.2%) 571 14% 7.4 (4.2) 56% 44% 35% 23% 1 (0.8%) 24 (19.0%) Disease characteristics CD4 count (median, cells/uL) CD4 <350 cells/uL (%) Duration of prior ARVs, years (mean, sd) Use of PI at screening (%) Use of NNRTI at screening (%) On their first NRTI combination PI naïve Hep B Surface Antigen, positive, n (%) Hep C Antibody, positive, n (%) DRV/r + 2NRTI (n=129) DRV/r (n=127)

  14. MONET: Primary Efficacy Analysis:HIV RNA <50 copies/mL at Week 48, TLOVR, S = F Per Protocol analysis (PP) Intent to Treat analysis (ITT) Primary analysis • 1.6%; lower limit 95%CI: -10.1% • 1%; lower limit 95%CI: -9.9% 100 87.8% 86.2% 85.3% 84.3% 90 80 HIV RNA <50 by Week 48 (%) 70 60 50 40 30 20 10 0 DRV/r + 2NRTI (PP) DRV/r mono (PP) DRV/r + 2NRTI (ITT) DRV/r mono (ITT) N=129 N=123 N=123 N=127 Table EFF 4-5 J. Arribas et al, IAS Conference, Cape Town, SA, 21 July 2009, TUAB106-LB

  15. MONET: Patient outcomes in DRV/r monotherapy (ITT) Baseline DRV/r monotherapy: n=127 Missing data n=0 HIV RNA>50 x2: n=11 (TLOVR) d/c or changed treatment, n=9 Treatment period HIV RNA<50: 107 HIV RNA<50: 10 HIV RNA>50: 1 HIV RNA<50: 7 HIV RNA>50: 2 Last visit HIV RNA<50: 97.6% 124/127

  16. Tamaño muestral Arribas JR. J Acquir Immune Defic Syndr 2005;40:280–287. Pulido F et al. AIDS. 2008 Jan 11;22(2):F1-9. Nunes EP. et al., XVI IAC,Toronto, Canada, 2006; #TUAB0102. Wilkin TJ et al. The Journal of Infectious Diseases 2009 Feb 1. Kalström O. J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):417-22. Pulido et al. GESIDA 2009 PO-69. Katlama et al. 5th IAS. #WELBB102. Arribas et al . AIDS (in press)

  17. Endpoints primarios

  18. Conclusiones

  19. 100 94 89.8 90 80 70 60 50 Percent without failure 40 30 OK 20 Triple 10 0 48 weeks OK04 Primary endpoint:Proportion without therapeutic failure at Week 48* Week 48 difference (Triple - OK) and 95% CI: - 4.2% (-11.8% to 3.4 %) * Patients in the monotherapy arm who reached and maintained < 50 c/mL after resuming baseline nucleosides are not considered as failures (n = 4) Pulido F et al. AIDS. 2008 Jan 11;22(2):F1-9.

  20. Sensitivity analysis of virological outcomes at 48 weeks. OK04. Response rate MT vs T Difference between treatment arms 95% confidence intervals Analysis -12% +12% 0% -5.7% +3.9% -15.3% < 50 HIV RNA copies/mL (TLOVR) 82.5% vs 88.2% -1.8% +7.3% -10.9% < 500 HIV RNA copies/mL (TLOVR) 86.4% vs 88.2% -8.2% -15.5% -0.8% < 50 HIV RNA copies/mL (OT) 88.5% vs 96.7% -4% +1.4% -10.4% < 500 HIV RNA copies/mL (OT) 92.7% vs 96.7% Lopinavir + 2 nucs better LPV/r Monotherapy better Pulido F et al. AIDS. 2008 Jan 11;22(2):F1-9.

  21. MONET trial: sensitivity analyses Difference in 48 week HIV RNA response rate between DRV/r mono and DRV/r + 2NRTI arms (95% confidence intervals) Analysis -12% 0% -1.8% -7.0% +3.5% PP, HIV RNA <200, TLOVR, switch equals failure 94.8% vs 96.6% -1.6% +4.2% -7.4% ITT, HIV RNA <50, TLOVR, switch included(S  F) 93.5% vs 95.1% -9.5% -3.2% +3.1% Observed HIV RNA <50 91.3% vs 94.6% -0.8% +2.6% -4.2% Observed HIV RNA <200 97.6% vs 98.4% DRV/r + 2NRTI better DRV/r + 2NRTI better

  22. Conclusiones • Darunavir/ritonavir es el primer IP potenciado que usado como monoterapia muetra una eficacia no inferior comparado a la triple terapia para el mantenimiento de la supresión virológica.

  23. Pulido F et al. Antivir Ther. 2009;14(2):195-201.

  24. Pharmacokinetic Considerations for Approved and Investigational Once-daily NRTIs Investigational Approved Approved Approved Approved QD as QD or BID as QD or BID as QD as QD 50 45 40 35 30 Hours 25 24 hours 20 ** * 15 12 hours 10 ** 5 0 ZDV d4T ABC 3TC ddI FTC TDF Indicates range where available Serum half-life Intracellular half-life * Piliero, et al. 43rd ICAAC, Chicago, 2003. ** Anderson, et al. AIDS 2003; 17(15):2159-2168. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51(RR-7):1-64

  25. ARTEMIS: percentage of patients with HIV-1 RNA <50 copies/mL at Week 96 by adherence p=0.3312 p<0.0001 82%(n=269) 78%(n=252) 76%(n=55) 53%(n=70) Patients with <50 copies/mL at Week 96 Adherent Sub-optimally Adherent Sub-optimally adherent adherent Darunavir/r LPV/r Note: adherence based on average % adherence Week 4 through Week 96 Nelson M, et al. 16th CROI 2009. Abstract 575

  26. *Over 12-hour dosing interval; ‡HIV-infected patients and healthy volunteers following light meal, mean; §Healthy volunteers following light meal, mean; ¶HIV-infected patients following light meal, mean

  27. Potencial Inhibitorio Instantáneo Shen L et al. Nat Med. 2008 Jul;14(7):762-6.

  28. MONET: Drug resistance Genotypic results DRV/r + 2NRTI N=129 DRV/r mono N=127 Patients with at least 1 successful genotype 13 22 No primary PI, DRV or NRTI mutations 21/22 (96%) 12/13 (92%) M184V 1 0 Primary IAS-USA PI mutations 1 1 DRV mutations 0 1 1 patient per arm had any evidence of genotypic resistance No patients had phenotypic resistance to DRV J. Arribas et al, IAS Conference, Cape Town, SA, 21 July 2009, TUAB106-LB

  29. Darunavir en LCR Yilmaz A. AIDS Research And Human Retroviruses. Volume 25, Number 4, 2009 Letendre S. ICAAC 2009. Poster #45

  30. Grade 1-4 Nervous System Adverse Events MONET DRV/r + 2NRTI N=129 DRV/r N=127 Total Areflexia Burning sensation Carotid artery stenosis Disturbance in attention 21 (16.3%) 1 1 0 1 20 (15.7%) 0 0 1 0 Dizziness Dysgeusia Headache Hypoasthaesia 3 1 9 1 1 1 10 2 Intracranial hypotension Nervous system disorder Parasthaesia Post herpetic neuralgia 0 1 0 0 1 0 2 1 Radiculitis Sciatica 2 1 0 0 Syncope Tremor 0 1 2 0 Trigeminal neuralgia 0 1 Data on file.

  31. Grade 1-4 Psychiatric Adverse Events DRV/r + 2NRTI N=129 DRV/r N=127 Total Anxiety disorder Apathy Depression Drug dependence 12 (9.3%) 1 0 3 2 12 (9.4%) 0 1 7 0 Insomnia Libido decreased Nightmare Obsessive-compulsive disorder 3 1 1 0 0 1 0 1 Psychotic disorder Sleep disorder Stress 0 5 1 1 4 0 Data on file.

  32. SAVE $1000 a month!! Arribas et al. TUAB106-LB

  33. Annual French Costs of ARV’s Annual French cost per person €12900 €12820 €10431 €6400

  34. MONOTERAPIA CON DARUNAVIR/RITONAVIR • En pacientes con supresión virológica mantenida, una pauta simple QD con Darunavir/ritonavir (800/100) usada en monoterapia ha demostrado en dos estudios la no inferioridad frente a la continuacion de una pauta triple basada en IPs o NNRTIs • El beneficio económico de esta pauta es importante • Otro tipo de beneficios (metabólicos, distribución grasa, preservación de opicones futuras de tratamiento) están aún por demostrar.

More Related